Screener
Charles River Laboratories CRL Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Accrued liabilities | 380,101 | 270,085 |
| Other current liabilities | 222,792 | 222,158 |
| Total current liabilities | 1,134,746 | 1,120,315 |
| Long-term debt, net and finance leases | 2,619,985 | 2,136,360 |
| Operating lease right-of-use liabilities | 407,708 | 434,048 |
| Deferred tax liabilities | 78,668 | 95,203 |
| Other long-term liabilities | 402,511 | 138,302 |
| Total liabilities | 4,643,618 | 3,924,228 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's long-term debt?
- Charles River Laboratories (CRL) reported long-term debt of $2.62B in Q2 2026.
- How has Charles River Laboratories's long-term debt changed year-over-year?
- Charles River Laboratories's long-term debt increased by 12.3% year-over-year, from $2.33B to $2.62B.
- What is the long-term trend for Charles River Laboratories's long-term debt?
- Over 5 years (2020 to 2025), Charles River Laboratories's long-term debt has grown at a 2.1% compound annual growth rate (CAGR), from $1.93B to $2.14B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Charles River Laboratories's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude